G1 Therapeutics’ (GTHX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a report issued on Thursday, Benzinga reports. HC Wainwright currently has a $9.00 price target on the stock. HC Wainwright also issued estimates for G1 Therapeutics’ FY2026 earnings at $0.72 EPS.

A number of other research analysts have also commented on GTHX. Wedbush reaffirmed an outperform rating and set a $5.00 price target (up previously from $4.00) on shares of G1 Therapeutics in a research report on Wednesday, February 28th. Needham & Company LLC reaffirmed a buy rating and set a $12.00 price target on shares of G1 Therapeutics in a research report on Wednesday.

G1 Therapeutics Stock Performance

Shares of GTHX traded up $0.05 on Thursday, reaching $4.49. 574,426 shares of the company’s stock traded hands, compared to its average volume of 665,254. The stock has a market cap of $234.74 million, a PE ratio of -7.24 and a beta of 1.71. G1 Therapeutics has a 52-week low of $1.08 and a 52-week high of $5.00. The stock’s 50 day simple moving average is $3.94 and its two-hundred day simple moving average is $3.09. The company has a current ratio of 2.94, a quick ratio of 3.45 and a debt-to-equity ratio of 1.34.

G1 Therapeutics (NASDAQ:GTHX) last issued its quarterly earnings results on Wednesday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. The firm had revenue of $14.48 million for the quarter, compared to the consensus estimate of $15.21 million. During the same period last year, the firm earned ($0.53) EPS. On average, analysts forecast that G1 Therapeutics will post -0.59 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Rajesh Malik sold 28,600 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $4.62, for a total value of $132,132.00. Following the sale, the insider now owns 169,938 shares in the company, valued at approximately $785,113.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 8.23% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On G1 Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Financial Advocates Investment Management purchased a new stake in shares of G1 Therapeutics during the 4th quarter valued at about $39,000. Capstone Investment Advisors LLC purchased a new stake in G1 Therapeutics during the 4th quarter valued at approximately $76,000. Jump Financial LLC purchased a new stake in G1 Therapeutics during the 4th quarter valued at approximately $105,000. Choreo LLC purchased a new stake in G1 Therapeutics during the 4th quarter valued at approximately $107,000. Finally, Creative Financial Designs Inc. ADV grew its holdings in G1 Therapeutics by 98.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock valued at $108,000 after buying an additional 17,475 shares in the last quarter. 24.21% of the stock is owned by institutional investors.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.